Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2001

View Archived Issues

HIV vaccine candidate evaluated in phase I trials

Lundbeck's psychopharmacological drug pipeline

Neurological drugs in Lundbeck's pipeline

Analysis of study results with topiramate in diabetic neuropathic pain

Human testing of injectable urethral bulking agent in progress

Organon plans to continue development of the Ampakine Org-24448

Novo Nordisk's rapid-acting insulin analogue now available in U.S.

More flexible and personalized therapy now possible with NeoRecormon

TAK-083 highly effective in the laboratory and in animals against H. pylori

Free I2 as an effective oxidant in human sperm

ATLAS study: sequence of events in heart failure progression and protective effects of lisinopril

Allovectin-7 phase III registration trial in metastatic melanoma now fully enrolled

Longer acting treatment for anemia in chronic renal failure cleared for U.S. launch

Amgen elects not to develop Guilford's neuroimmunophilin ligands

Muscarinic receptor binding profile of YM-905 correlated with pharmacological activity

Tiagabine as a potential treatment option for overactive bladder

Taxanes with potent antitumor activity reported by Florida State

New antimycobacterial compounds from Genzyme interfere with cell wall biosynthesis

Bayer and Millennium announce identification of 140 disease-relevant drug targets

Nippon Kayaku prepares new agents for use in photochemical therapy of tumors

Pharmos expands pivotal phase III trial of dexanabinol into U.K.

First evidence that overexpression of dopamine D2 receptor reduces alcohol intake

Erythromycin derivatives identified by Hokuriku active against H. pylori

Two series of factor Xa inhibitors disclosed recently by Cor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...